GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Cyclically Adjusted PB Ratio

Zealand Pharma A/S (Zealand Pharma A/S) Cyclically Adjusted PB Ratio : 25.55 (As of May. 22, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Cyclically Adjusted PB Ratio?

As of today (2024-05-22), Zealand Pharma A/S's current share price is $90.70. Zealand Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.55. Zealand Pharma A/S's Cyclically Adjusted PB Ratio for today is 25.55.

The historical rank and industry rank for Zealand Pharma A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

ZLDPF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.3   Med: 9.87   Max: 31.77
Current: 24.79

During the past years, Zealand Pharma A/S's highest Cyclically Adjusted PB Ratio was 31.77. The lowest was 3.30. And the median was 9.87.

ZLDPF's Cyclically Adjusted PB Ratio is ranked worse than
97.24% of 651 companies
in the Biotechnology industry
Industry Median: 1.71 vs ZLDPF: 24.79

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zealand Pharma A/S's adjusted book value per share data for the three months ended in Mar. 2024 was $6.641. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.55 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Zealand Pharma A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Cyclically Adjusted PB Ratio Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.79 10.84 6.62 8.96 16.10

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.55 10.85 13.27 16.10 28.16

Competitive Comparison of Zealand Pharma A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Zealand Pharma A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cyclically Adjusted PB Ratio falls into.



Zealand Pharma A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zealand Pharma A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=90.70/3.55
=25.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zealand Pharma A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.641/118.4000*118.4000
=6.641

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.411 99.700 2.863
201409 2.419 99.700 2.873
201412 1.851 99.400 2.205
201503 1.341 100.200 1.585
201506 1.069 100.300 1.262
201509 1.022 100.200 1.208
201512 1.547 99.800 1.835
201603 1.119 100.200 1.322
201606 0.677 100.600 0.797
201609 1.286 100.200 1.520
201612 1.542 100.300 1.820
201703 1.420 101.200 1.661
201706 1.070 101.200 1.252
201709 3.334 101.800 3.878
201712 2.667 101.300 3.117
201803 2.358 101.700 2.745
201806 1.616 102.300 1.870
201809 6.322 102.400 7.310
201812 5.541 102.100 6.426
201903 5.195 102.900 5.978
201906 4.605 102.900 5.299
201909 5.807 102.900 6.682
201912 4.934 102.900 5.677
202003 4.871 103.300 5.583
202006 6.841 103.200 7.849
202009 6.340 103.500 7.253
202012 5.051 103.400 5.784
202103 6.165 104.300 6.998
202106 5.160 105.000 5.819
202109 4.346 105.800 4.864
202112 3.262 106.600 3.623
202203 2.432 109.900 2.620
202206 1.555 113.600 1.621
202209 1.053 116.400 1.071
202212 2.257 115.900 2.306
202303 1.870 117.300 1.888
202306 4.315 116.400 4.389
202309 4.460 117.400 4.498
202312 3.992 116.700 4.050
202403 6.641 118.400 6.641

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma A/S  (OTCPK:ZLDPF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zealand Pharma A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (Zealand Pharma A/S) Headlines